He, Gu

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy

Protein Degradation and InhibitorsComputational Drug Discovery Methods

Cited by 396

Protein SUMOylation modification and its associations with disease

Yang, Y., He, Y., Wang, X., liang, Z., He, G., Zhang, P., Zhu, H., Xu, N., & Liang, S. (2017) · Open Biology

Ubiquitin and proteasome pathwaysCancer-related gene regulation

Cited by 216

The Multiple Roles of Interferon Regulatory Factor family in Health and Disease

Wang, L., Zhu, Y., Zhang, N., Xian, Y., Tang, Y., Ye, J., Reza, F., He, G., Wen, X., & Jiang, X. (2024) · Signal Transduction and Targeted Therapy

interferon and immune responsesCytokine Signaling Pathways and Interactions

Cited by 178

Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma

Wang, B., Peng, F., Huang, W., Zhou, J., Zhang, N., Sheng, J., Haruehanroengra, P., He, G., & Han, B. (2020) · Acta Pharmaceutica Sinica B

Heterocyclic Compound Synthesis and BioactivityCancer-related Molecular Pathways

Cited by 73

Dual‐target inhibitors of bromodomain and extra‐terminal proteins in cancer: A review from medicinal chemistry perspectives

Feng, L., Wang, G., Chen, Y., He, G., Liu, B., Liu, J., Chiang, C., & Ouyang, L. (2022) · Medicinal Research Reviews

Protein Degradation and InhibitorsHistone Deacetylase Inhibitors Research

Cited by 65